NDC 0944-2721-03 - HYQVIA
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0944-2721
- Requested NDC
- 0944-2721-03
- Package NDCs from labels
- 0944-2721-03
- Manufacturer
- Takeda Pharmaceuticals America, Inc. | Baxalta Belgium Manufacturing SA | Catalent Indiana, LLC | Takeda Manufacturing Austria AG | Baxalta US Inc.
- Effective date
- 2026-06-18
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| HYQVIA | Takeda Pharmaceuticals America, Inc. | Baxalta Belgium Manufacturing SA | Catalent Indiana, LLC | Takeda Manufacturing Austria AG | Baxalta US Inc. | 2026-06-18 | PLASMA DERIVATIVE |
| HYQVIA - Bamboo US BidCo LLC | Bamboo US BidCo LLC | 2024-12-17 | PLASMA DERIVATIVE |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0944-2721-03 | HYQVIA | 2.5 mL in 1 VIAL, GLASS | SOLUTION | 2.5 mL | 160 [USP'U] in 1mL | 22 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 0944-2721 | HYQVIA (IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.] | 19 | Unmatched | 20241120_7ca2c26f-4be2-48cd-be5b-486e350654ba.zip |
| 0944-2721 | HYQVIA (IMMUNE GLOBULIN INFUSION 10% (HUMAN) WITH RECOMBINANT HUMAN HYALURONIDASE) KIT [BAMBOO US BIDCO LLC] | 3 | Unmatched | 20241219_1a52ca88-a13c-7c67-e063-6394a90a1f67.zip |
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Isolyte S | SODIUM CHLORIDE, SODIUM GLUCONATE, SODIUM ACETATE, POTASSIUM CHLORIDE, AND MAGNESIUM CHLORIDE | B. Braun Medical Inc. | 7e8fe27f-ff82-48c1-9bf6-3c589c8e985d | 2026-10-12 | Warnings, Adverse reactions | 451W47IQ8X |
| Darzalex Faspro | DARATUMUMAB AND HYALURONIDASE-FIHJ (HUMAN RECOMBINANT) | Janssen Biotech, Inc. | 4bb241af-4299-4373-8762-2d6709515db0 | 2026-10-12 | Warnings, Adverse reactions | 743QUY4VD8 |
| Sodium Chloride | SODIUM CHLORIDE | CODAN US CORPORATION | aa06e286-75c6-4d7a-959f-6008d38aa6e5 | 2026-10-08 | Warnings, Adverse reactions | 451W47IQ8X |
| GoLYTELY | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Braintree Laboratories, Inc. | 57d22b0b-1ae0-4203-babc-f3bac17bd1c9 | 2026-10-08 | Warnings, Adverse reactions | 451W47IQ8X |
| PEG-3350 and Electrolytes | POLYETHYLENE GLYCOL 3350, SODIUM SULFATE ANHYDROUS, SODIUM BICARBONATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE | Affordable Pharmaceuticals, LLC | 448db7a5-1fea-4bf3-b1f5-e9d027a36603 | 2026-10-08 | Warnings, Adverse reactions | 451W47IQ8X |
| PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride | POLYETHYLENE GLYCOL 3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE | Affordable Pharmaceuticals, LLC | 89ca6d56-527a-4be2-baea-531156f0a7be | 2026-10-08 | Warnings, Adverse reactions | 451W47IQ8X |
| Sodium Chloride | SODIUM CHLORIDE | Nextgen Pharmaceuticals LLC | 28f79c75-82d2-4912-81fc-a723b5ccf4c1 | 2026-10-08 | Warnings, Adverse reactions | 451W47IQ8X |
| Sodium Chloride | SODIUM CHLORIDE | SOLA Pharmaceuticals, LLC | 4d0bfd28-460a-48ba-bd17-cf75e56d62f4 | 2026-10-08 | Warnings, Adverse reactions | 451W47IQ8X |
| Sodium Chloride | SODIUM CHLORIDE | LABORATORIOS GRIFOLS SA | eb811d79-fdb8-1f1a-c2ad-1cc4bfc7eadf | 2026-10-08 | Warnings, Adverse reactions | 451W47IQ8X |
| MEIJER Saline | NASAL | MEIJER | a5c6d800-078a-4b66-9d4c-cf3c53f5c138 | 2026-10-05 | Warnings | 451W47IQ8X |
| Personal CARE Saline Nasal | SODIUM CHLORIDE | Delta Brands Inc. | 5ccaf7a1-6891-eac4-e063-6294a90a829f | 2026-10-02 | Warnings | 451W47IQ8X |
| ASCENIV | HUMAN IMMUNOGLOBULIN G | ADMA Biologics, Inc. | d74f4360-3b51-496c-96fb-84c3976958d2 | 2026-09-29 | Boxed warning, Warnings, Adverse reactions | 66Y330CJHS |
| BIVIGAM | IMMUNE GLOBULIN INTRAVENOUS (HUMAN) 10% | ADMA Biologics, Inc. | a2244aa0-a6d0-11df-b385-0002a5d5c51b | 2026-09-29 | Boxed warning, Warnings, Adverse reactions | 1809421 1809414 66Y330CJHS |
| Dextrose And Sodium Chloride | DEXTROSE AND SODIUM CHLORIDE | B. Braun Medical Inc. | 8e6569ce-9714-497f-a94b-c6975c1d76f6 | 2026-09-28 | Warnings, Adverse reactions | 451W47IQ8X |
| Sodium Chloride Hypertonicity Ophthalmic | SODIUM CHLORIDE | Rugby Laboratories | 7546770d-bc12-44b8-9fe0-fc3f5e1d12d1 | 2026-09-24 | Warnings | 451W47IQ8X |
| Phesgo | PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF | Genentech, Inc. | 27dd5e6b-72cd-458d-a015-cf4dab5800da | 2026-09-23 | Boxed warning, Warnings, Adverse reactions | 743QUY4VD8 |
| Sodium Chlorode Hypertonicity Ophthalmic Solution | SODIUM CHLORIDE | Rugby Laboratories | 822d25c0-71b3-421d-b702-4cded0c4ca32 | 2026-09-23 | Warnings | 451W47IQ8X |
| Rituxan Hycela | RITUXIMAB AND HYALURONIDASE | Genentech, Inc. | 3e5b7e82-f018-4eaf-ae78-d6145a906b20 | 2026-09-23 | Boxed warning, Warnings, Adverse reactions | 743QUY4VD8 |
| BURBLE | SODIUM CHLORIDE | LETS BURBLE, INC. | 17f48d4f-907c-3829-e063-6394a90ab202 | 2026-09-22 | Warnings | 451W47IQ8X |
| Herceptin Hylecta | TRASTUZUMAB AND HYALURONIDASE-OYSK | Genentech, Inc. | ebf30894-41cf-480c-8bc3-56f592a13813 | 2026-09-22 | Boxed warning, Warnings, Adverse reactions | 743QUY4VD8 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.